On 23 September 2026 the FDA’s Center for Drug Evaluation and Research issued a warning letter to the operator of www.onlinegenericmedicine.com, an internet pharmacy, after reviewing the site on 26 August and 2 September. The agency said the site offered U.S. consumers an injectable semaglutide product sold as “Semanat Injection (Semaglutide)”, which has no FDA … Read more
On September 18, 2026, the FDA issued a warning letter to Empower Clinic Services, LLC, doing business as Empower Pharmacy, of Houston, Texas, following an inspection of its facility in November 2025. The agency said the pharmacy compounded tirzepatide/niacinamide and semaglutide/cyanocobalamin products that appear to be essentially copies of FDA-approved drugs — the legal line … Read more
The FDA’s Center for Drug Evaluation and Research issued warning letters dated 24 August 2026 to five online peptide sellers — TXP Innovations LLC dba Tex Peptides, Royal Peptides LLC, NuScience Peptides LLC, Peptide Partners LLC and Peak Performance Peptides — posted 1 September 2026. Each followed a July 2026 review of the firm’s website … Read more
On 24 August 2026 the US Food and Drug Administration issued a warning letter to BioDrive, Inc. over Evolv GLP-1 Biomimetic, a dietary supplement whose labeling declares “Saccharomyces cerevisiae S288C EV-1 Peptide” as a dietary ingredient. FDA classed that ingredient as a new dietary ingredient and found the product adulterated under section 402(f)(1)(B) of the … Read more
On 17 June 2026 the FDA’s Center for Drug Evaluation and Research issued a warning letter to Wholesale Peptide of Brooksville, Florida, after reviewing the firm’s website in May 2026. The letter names two products, “Prostamax” and “Gonadorelin”, as unapproved new drugs under section 505(a) of the FD&C Act, quoting site copy stating that Prostamax … Read more
The FDA issued a further round of warning letters on 8 June 2026, including to Altru Telehealth, Medica Weight Loss and FITISH, continuing the enforcement line it opened in September 2025 and widened in March 2026. Sources: Altru Telehealth · Medica Weight Loss · FITISH
On 31 March 2026 the FDA’s Center for Drug Evaluation and Research issued warning letters to five websites selling injectable peptides to US buyers: Lovega LLC dba Pink Pony Peptides, Gram Peptides, Prime Sciences, Mile High Compounds and PekCura Labs. Each cites unapproved new drugs sold over the internet under sections 301(d) and 505(a) of … Read more
The FDA issued warning letters to 30 telehealth companies over false or misleading claims made about compounded GLP-1 products sold on their websites. It was the second wave of letters aimed at telehealth firms since the agency opened a broader campaign against misleading direct-to-consumer drug advertising in September 2025, and the largest single action against … Read more